Medytox Reports 74% Increase in Third Quarter Operating Profit

Medytox reported a growth rate of over 70% in its operating profit for the third quarter of this year, driven by strong overseas exports of its core botulinum toxin products and cost reductions.
 
The company announced on November 10 that its consolidated sales for the third quarter reached 59.3 billion won, with an operating profit of 15.5 billion won and a net profit of 11.6 billion won.
 
While sales decreased by 2.8% compared to the same period last year, operating profit and net profit increased by 74.5% and 61.4%, respectively. The company attributed this improvement to better cost management and reduced selling and administrative expenses.
 
By business segment, the botulinum toxin products generated 35.5 billion won in sales, leading overall performance. In the domestic market, the 'Coretox' product maintained stable sales. Internationally, the dual-brand strategy featuring both the existing flagship product 'Medytoxin' and the next-generation toxin 'Neurotox' resulted in a 17% increase in sales compared to the previous year.
 
The domestically developed drug 'Newbeau,' a fat-reducing injection containing the CA ingredient, has also successfully established itself in the local market, achieving its sales target for the year ahead of schedule.
 
A Medytox representative stated, "We will strengthen our existing toxin and filler businesses while securing new growth foundations to improve profitability and enhance competitiveness. We are committed to focusing our efforts to achieve record sales this year."




* This article has been translated by AI.